BOT botanix pharmaceuticals ltd

Ann: March 2025 Quarterly Activities Report and Appendix 4C, page-147

  1. 2,251 Posts.
    lightbulb Created with Sketch. 448
    Answered my own question pretty quickly using chatgpt.

    So Anacor sold out before they even had FDA approval.

    Howie was involved in Anacor Pharmaceuticals; developed crisaborole, a topical treatment for mild-to-moderate eczema (atopic dermatitis). In May 2016, Pfizer acquired Anacor for $5.2 billion, gaining access to crisaborole, which was under FDA review at the time .pharmaphorum+12Pfizer+12Fierce Biotech+12The U.S. Food and Drug Administration (FDA) approved crisaborole, marketed as Eucrisa, in December 2016 for patients aged 2 years and older . Eucrisa is a non-steroidal phosphodiesterase 4 (PDE-4) inhibitor applied topically twice daily .

    Howie also involved in Medicis which was acquired by Bausch Health. Medicis had a portfolio of dermatology treatments at the time. Sold for $99us and $44us respectively.

    I'm trying to gauge at what point management would have an appetite for entertaining buy out offers. Looks like at any point in the development and delivery phase

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
17.0¢
Change
0.010(6.25%)
Mkt cap ! $333.3M
Open High Low Value Volume
16.0¢ 18.0¢ 16.0¢ $3.403M 19.98M

Buyers (Bids)

No. Vol. Price($)
1 11400 17.0¢
 

Sellers (Offers)

Price($) Vol. No.
17.5¢ 1048293 11
View Market Depth
Last trade - 16.10pm 25/07/2025 (20 minute delay) ?
BOT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.